Dualitas Therapeutics

Dualitas Therapeutics is a preclinical-stage bispecific antibody company that launched from stealth in September 2025 with a $65 million Series A financing. The company's proprietary DualScreen discovery engine screens up to 100,000+ unique bispecific combinations to identify synergistic antibody pairs that leverage cell-surface proximity biology. The company's lead programs, DTX-103 (allergic disease) and DTX-102 (autoimmune disease), have demonstrated differentiated preclinical profiles when benchmarked against commercially available therapies, showing greater potency, enhanced efficacy, and faster onset of action compared to validated standard-of-care treatments.[3][6]